OBJECTIVE: The aim of this study on primary breast cancer patients undergoing adjuvant tamoxifen treatment was to determine how their perceptions of the treatment and their experience of side-effects contributed to their adherence to the treatment. METHODS: A consecutive series of primary breast cancer patients eligible for tamoxifen therapy were studied qualitatively by conducting semi-structured in-depth interviews at two French cancer centres. RESULTS: The women aged 35-65 (N=34) were struggling with several issues involving their understanding and experience of the treatment, which have not been documented so far. These issues included confusion about the 'hormonal' nature and activity of tamoxifen and the etiology of the changes in their menopausal status, as well as the symbolic associations formed by patients about the paradox of taking a treatment that has aging effects but saves lives. CONCLUSIONS: This study shows the great physical burden often associated with tamoxifen treatment and brings to light women's own complex representations of the treatment and their interpretation of the side-effects. Better communication between health-care providers and patients should ultimately help to prevent refusal or discontinuation of tamoxifen treatment. Copyright 2009 John Wiley & Sons, Ltd.
OBJECTIVE: The aim of this study on primary breast cancerpatients undergoing adjuvant tamoxifen treatment was to determine how their perceptions of the treatment and their experience of side-effects contributed to their adherence to the treatment. METHODS: A consecutive series of primary breast cancerpatients eligible for tamoxifen therapy were studied qualitatively by conducting semi-structured in-depth interviews at two French cancer centres. RESULTS: The women aged 35-65 (N=34) were struggling with several issues involving their understanding and experience of the treatment, which have not been documented so far. These issues included confusion about the 'hormonal' nature and activity of tamoxifen and the etiology of the changes in their menopausal status, as well as the symbolic associations formed by patients about the paradox of taking a treatment that has aging effects but saves lives. CONCLUSIONS: This study shows the great physical burden often associated with tamoxifen treatment and brings to light women's own complex representations of the treatment and their interpretation of the side-effects. Better communication between health-care providers and patients should ultimately help to prevent refusal or discontinuation of tamoxifen treatment. Copyright 2009 John Wiley & Sons, Ltd.
Authors: C O'Brien; J Kelly; E A Lehane; V Livingstone; B Cotter; A Butt; L Kelly; M A Corrigan Journal: World J Surg Date: 2015-10 Impact factor: 3.352
Authors: Caitriona Cahir; Stephan U Dombrowski; Catherine M Kelly; M John Kennedy; Kathleen Bennett; Linda Sharp Journal: Support Care Cancer Date: 2015-03-07 Impact factor: 3.603
Authors: Stephanie Brooke Wheeler; Racquel Elizabeth Kohler; Katherine Elizabeth Reeder-Hayes; Ravi K Goyal; Kristen Hassmiller Lich; Alexis Moore; Timothy W Smith; Cathy L Melvin; Hyman Bernard Muss Journal: J Cancer Surviv Date: 2014-05-28 Impact factor: 4.442
Authors: Jennifer C Livaudais; Dawn L Hershman; Laurel Habel; Lawrence Kushi; Scarlett Lin Gomez; Christopher I Li; Alfred I Neugut; Louis Fehrenbacher; Beti Thompson; Gloria D Coronado Journal: Breast Cancer Res Treat Date: 2011-09-16 Impact factor: 4.872
Authors: Dawn L Hershman; Lawrence H Kushi; Grace Clarke Hillyer; Ellie Coromilas; Donna Buono; Lois Lamerato; Dana H Bovbjerg; Jeanne S Mandelblatt; Wei-Yann Tsai; Xiaobo Zhong; Judith S Jacobson; Jason D Wright; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2016-04-16 Impact factor: 4.872
Authors: Jennifer C Livaudais; Andrea Lacroix; Rowan T Chlebowski; Christopher I Li; Laurel A Habel; Michael S Simon; Beti Thompson; Deborah O Erwin; F Allan Hubbell; Gloria D Coronado Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-12-28 Impact factor: 4.254
Authors: Caitlin C Murphy; L Kay Bartholomew; Melissa Y Carpentier; Shirley M Bluethmann; Sally W Vernon Journal: Breast Cancer Res Treat Date: 2012-06-12 Impact factor: 4.872